Abbott begins Spirit Prime study

Abbott will use results from the Spirit Prime study to support regulatory filings of the Xience Prime system, it has claimed.

The company has announced the initiation of the clinical trial to test the effectiveness of its next-generation everolimus eluting coronary stent, which is being examined as a device to treat coronary artery disease.

Principal investigator of the study Dr Marco A Costa explained the device carries the same drug and polymer as the Xience V product.

The platform and delivery balloon are designed to be “highly deliverable”, he noted, adding this means it has the potential to simplify challenging cases.

“Xience V is used routinely in my practice, and I look forward to studying the enhanced features and sizes of Abbott’s next-generation drug eluting stent, Xience Prime,” he stated.

Earlier this month, Abbott launched the sixth-generation Emboshield Nav6 Embolic Protection System to use in carotid artery stenting procedures.

Dr D Christopher Metzger from the Holston Valley Medical Center said the device provides excellent steerable wire options and a short basket length.

He asserted the improvements from its predecessor made it an “outstanding” product.